[Annual Report] Central and Eastern…
Fierce Biotech: Chinese Vaccine Developer…
Multicenter, prospective, double-blind, randomized, comparative, clinical study of the efficacy and tolerability of trastuzumab drugs in combination with neoadjuvant chemotherapy and subsequent adjuvant monotherapy in patients with HER2-positive operable breast cancer. Key milestones: development of the electronic CRFs; data validation; database lock.
Download the pdf document with the full results of the case study here.